Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Quest Diagnostics director Tracey Doi received an equity award tied to her board service. She acquired 1,142 shares of Common Stock as a grant with no cash price per share, described in the footnotes as an award of restricted stock units. After this award and related dividend reinvestments, she directly holds 7,748 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Doi Tracey

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,142	$0.00	--

Holdings After Transaction: Common Stock — 7,748 shares (Direct, null)

Footnotes (1)

Represents an award of restricted stock units. The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors.

Key Figures

Equity award size: 1,142 shares Grant price per share: $0.00 per share Shares owned after grant: 7,748 shares

3 metrics

Equity award size 1,142 shares Grant of Common Stock on 2026-05-20

Grant price per share $0.00 per share Compensation-related grant, not open-market purchase

Shares owned after grant 7,748 shares Direct holdings following award and dividend reinvestment

Key Terms

restricted stock units, dividend reinvestment, Deferred Compensation Plan for Directors

3 terms

restricted stock units financial

"Represents an award of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

dividend reinvestment financial

"includes shares acquired via dividend reinvestment since the date of reporting person's last filing"

Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.

Deferred Compensation Plan for Directors financial

"pursuant to the Amended and Restated Deferred Compensation Plan for Directors."

A deferred compensation plan for directors is an arrangement that lets board members postpone receiving part of their pay until a later date—often retirement or a set future time—so the money can grow or be paid under specified conditions. Think of it like directing a portion of your paycheck into a locked savings account that pays out later; investors care because it creates future cash or stock obligations, signals how the company motivates and retains leadership, and can affect shareholder value through timing of payouts or potential dilution.

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 04:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doi Tracey

(Last)

(First)

(Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS

NEW JERSEY

07094

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	05/20/2026		A		1,142	A	$0	7,748⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents an award of restricted stock units.

2. The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors.

Remarks:

	Sean D. Mersten, Attorney in Fact for Tracey C. Doi	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Quest Diagnostics (DGX) director Tracey Doi report?

Director Tracey Doi reported receiving an equity award from Quest Diagnostics. The Form 4 shows she acquired 1,142 shares of Common Stock as a grant, described as restricted stock units, increasing her direct holdings to 7,748 shares after the transaction and related dividend reinvestments.

How many Quest Diagnostics (DGX) shares did Tracey Doi acquire in this Form 4?

Tracey Doi acquired 1,142 shares of Quest Diagnostics Common Stock. The transaction is coded as a grant or award, meaning it is compensation-related rather than an open-market purchase, and was received at a stated price of $0.00 per share according to the Form 4 data.

What are Tracey Doi’s Quest Diagnostics (DGX) holdings after this grant?

After this grant, Tracey Doi directly holds 7,748 Quest Diagnostics shares. This figure includes the 1,142-share award and shares accumulated through dividend reinvestment since her prior Form 4, as noted in the filing’s footnotes describing the deferred compensation plan for directors.

Was the Quest Diagnostics (DGX) insider transaction an open-market buy or a grant?

The Quest Diagnostics insider transaction was a grant, not an open-market buy. The Form 4 uses transaction code A, with a description of grant, award, or other acquisition, and a price per share of $0.00, indicating compensation-related restricted stock units rather than a market purchase.

What do the Quest Diagnostics (DGX) Form 4 footnotes say about the award?

The footnotes state the transaction represents an award of restricted stock units. They also explain the reported total includes shares acquired via dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors since Tracey Doi’s last Form 4 filing.